Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret L Moline

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Sleep Medicine Reviews|March 12, 2003
Sleep in women across the life cycle from adulthood through menopauseMargaret L Moline, Lauren Broch, Rochelle Zak, et al.
Current Drug Safety|June 10, 2014
Middle-of-the-night administration of sleep medication: a critical review of the effects on next morning driving abilityJoris C Verster, Aurora J A E van de Loo, Margaret L Moline, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 1, 2010
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its partsStefan J Cano, Holly B Posner, Margaret L Moline, et al.
Clinical Therapeutics|April 2, 2013
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adultsDavid J Greenblatt, Jerold S Harmatz, Thomas Roth, et al.
Journal of Clinical Pharmacology|November 9, 2013
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administrationDavid J Greenblatt, Jerold S Harmatz, Nikhilesh N Singh, et al.
Clinical Therapeutics|August 4, 2010
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind studyMartin R Farlow, Stephen Salloway, Pierre N Tariot, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Sleep Medicine Reviews|March 12, 2003
Sleep in women across the life cycle from adulthood through menopauseMargaret L Moline, Lauren Broch, Rochelle Zak, et al.
Current Drug Safety|June 10, 2014
Middle-of-the-night administration of sleep medication: a critical review of the effects on next morning driving abilityJoris C Verster, Aurora J A E van de Loo, Margaret L Moline, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 1, 2010
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its partsStefan J Cano, Holly B Posner, Margaret L Moline, et al.
Clinical Therapeutics|April 2, 2013
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adultsDavid J Greenblatt, Jerold S Harmatz, Thomas Roth, et al.
Journal of Clinical Pharmacology|November 9, 2013
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administrationDavid J Greenblatt, Jerold S Harmatz, Nikhilesh N Singh, et al.
Clinical Therapeutics|August 4, 2010
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind studyMartin R Farlow, Stephen Salloway, Pierre N Tariot, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
Pageof 1